Why the study?
The study aimed to evaluate the relationship of the triglyceride-glucose index to long-term mortality and appropriate shock therapy in patients with heart failure with reduced ejection fraction and an ICD.
Does the admission triglyceride-glucose (TyG) index predict long-term mortality and appropriate ICD therapy in patients with heart failure with reduced ejection fraction?
Does the admission triglyceride-glucose (TyG) index predict long-term mortality and appropriate ICD therapy in patients with heart failure with reduced ejection fraction?
The admission triglyceride-glucose index is an independent predictor of long-term mortality and appropriate ICD therapy in patients with HFrEF.
TyG index may aid mortality risk stratification in HFrEF; hypothesis-generating and requires prospective validation before guiding ICD decisions.
Background: In this study, the main aim was to evaluate the relation of the triglyceride-glucose (TyG) index to long-term mortality and proper shock therapy in patients with an implantable cardiac defibrillator (ICD) implanted for heart failure with reduced ejection fraction. Methods: This retrospective study group consisted of 773 patients treated with ICD for heart failure with reduced ejection fraction. The long-term prognostic effect of the TyG index among tertiles was evaluated regarding mortality and appropriate ICD therapy. Results: In the adjusted model, the mortality rates were 14.0% (hazard ratio: 2.24; 95% CI: 1.42-6.88) in tertile 2 and 23.3% (hazard ratio: 3.88; 95% CI: 1.84-14.38) in tertile 3. Conclusion: The TyG index was found to be an independent predictive marker for both long-term mortality and appropriate ICD therapy.
No takes yet. Share an insight, caveat, or question.
Özcan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: